 Tucked in its Q2 earnings release, Myovant Sciences Ltd NYSE: MYOV said that Pfizer Inc NYSE: PFE has notified its option decision for international rights to relugolix in oncology. Pfizer declined its option based on its assessment of its current strategic investment priorities in international markets. 